Phase 3
N=282
Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)
Sedation
Bottom Line
View on ClinicalTrials.gov: NCT05327296 ↗Enrolled (actual)
282
Serious AEs
21.9%
Results posted
Mar 2026
Primary outcome: Primary: Percentage of Time Sedation Depth is Maintained Within the Target Range, in Absence of Rescue Sedation, as Assessed According to the RASS Scale, in Isoflurane- vs Propofol-treated Patients — 72; 73.7 percentage of time — p=<.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Isoflurane (Drug); Propofol (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Sedana Medical
- Primary completion
- May 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Time Sedation Depth is Maintained Within the Target Range, in Absence of Rescue Sedation, as Assessed According to the RASS Scale, in Isoflurane- vs Propofol-treated Patients |
72; 73.7 | <.001 sig |
| SECONDARY Key Secondary: The Effect of Isoflurane vs Propofol on Use of Opioids During the Study Treatment Period |
-0.29; 0.03 | 0.0007 sig |
| SECONDARY Key Secondary: The Effect of Isoflurane vs Propofol on the Wake up Time at End of Study Drug Treatment |
13.0; 17.0 | 0.643 |
| SECONDARY Key Secondary: The Effect of Isoflurane vs Propofol on Cognitive Recovery After End of Study Drug Treatment |
20; 23; 9; 5; 12; 4 | 0.231 |
| SECONDARY Key Secondary: The Effect of Isoflurane vs Propofol on Spontaneous Breathing Effort During the Study Drug Treatment Period |
69.9; 54.6 | 0.003 sig |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Time From Sedation Termination to Extubation in Patients for Whom Study Drug is Terminated for Extubation |
67.5; 80.0 | 0.726 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Days Alive and Free of Mechanical Ventilation Through Study Day 30 |
19.6; 19.8 | 0.919 |
| SECONDARY Other Secondary: To Compare the Effect of Isoflurane vs Propofol on Days Alive and Free of the ICU |
12.5; 12.1 | 0.764 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Delirium and Coma Free Days Until 7 Days After End of Study Treatment |
1.9; 2.6 | 0.011 sig |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 30 Days After Randomization |
39; 21 | 0.266 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 3 Months After Randomization |
52; 27 | 0.271 |
| SECONDARY Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 6 Months After Randomization |
58; 34 | 0.106 |
| SECONDARY Other Secondary: Sedaconda ACD-S Device Deficiencies in Patients Receiving Isoflurane |
7 | — |
| SECONDARY Other Secondary: The Use of Restraints in Patients Receiving Isoflurane vs Propofol |
138; 73 | — |
Summary
This is a study to compare safety and efficacy of inhaled isoflurane administered via the Sedaconda ACD-S device system versus intravenous propofol for sedation of mechanically ventilated patients in the Intensive Care Unit (ICU) setting.
Eligibility Criteria
Inclusion Criteria
- Adults ≥18 years of age;
- Patients who are anticipated to require >12 hours of invasive mechanical ventilation and continuous sedation in the ICU; and
- Receipt of continuous sedation due to clinical need for sedation to RASS 72 hours;
- Severe neurological condition before ICU admission that causes the patient to lack ability to participate in the study (ie, unable to be assessed for RASS and CPOT);
- Ventilator tidal volume 1000 mL at Baseline;
- Need for extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2R), high frequency oscillation ventilation (HFOV), or high frequency percussive ventilation (HFPV) at Screening;
- Comfort care only (end of life care);
- Contraindication to propofol or isoflurane;
- Known or family history of MH;
- Severe hemodynamic compromise, defined as the need for norepinephrine ≥0.3 mcg/kg/min (or equivalent vasopressor dose) to maintain blood pressure within acceptable range, assumed to be mean arterial pressure ≥65 mmHg unless prescribed clinically;
- Allergy to isoflurane or propofol, or have propofol infusion syndrome.
- History of ventricular tachycardia/Long QT Syndrome;
- Requirement of IV benzodiazepine or barbiturate administration for seizures or dependencies, including alcohol withdrawal
- Neuromuscular disease that impairs spontaneous ventilation (eg, C5 or higher spinal cord injury, amyotrophic lateral sclerosis, etc);
- Concurrent enrollment in another study that, in the Investigator's opinion, would impact the patient's safety or assessments of this study;
- Participation in other study involving investigational drug(s) or devices(s) within 30 days prior to Randomization;
- Anticipated requirement of treatment with continuous infusion of a neuromuscular blocking agent for >4 hours;
- Female patients who are pregnant or breast-feeding;
- Imperative need for continuous active humidification through mechanical ventilation circuit;
- Attending physician's refusal to include the patient; or
- Inability to obtain informed consent.
Data sourced from ClinicalTrials.gov (NCT05327296). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.